Morrisette Taylor, Alosaimy Sara, Philley Julie V, Wadle Carly, Howard Catessa, Webb Andrew J, Veve Michael P, Barger Melissa L, Bouchard Jeannette, Gore Tristan W, Lagnf Abdalhamid M, Ansari Iman, Mejia-Chew Carlos, Cohen Keira A, Rybak Michael J
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center, University of Texas, Tyler, Texas, USA.
Open Forum Infect Dis. 2021 Jan 7;8(2):ofab002. doi: 10.1093/ofid/ofab002. eCollection 2021 Feb.
Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for . The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2-11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.
12名患者接受了奥马环素（OMC）治疗，作为多药治疗方案的一部分用于……。大多数感染起源于肺部（7/12；58.3%）。奥马环素治疗的中位（四分位间距）持续时间为6.2（4.2 - 11.0）个月。9/12（75.0%）的患者临床治疗成功。3名患者在治疗期间出现了可能的不良反应。
